Loading…
Indaptus Therapeutics, Inc. is projected to rise to $3.48 by 2027, a +32% move from its current price of $2.63. INDP is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.42 | $2.63 | $2.86 | -0.01% |
| Jul 14 | $2.33 | $2.63 | $2.97 | -0.02% |
| Jul 15 | $2.27 | $2.63 | $3.05 | -0.03% |
| Jul 16 | $2.22 | $2.63 | $3.12 | -0.04% |
| Jul 17 | $2.17 | $2.63 | $3.18 | -0.04% |
| Jul 18 | $2.13 | $2.63 | $3.24 | -0.05% |
| Jul 19 | $2.10 | $2.63 | $3.29 | -0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.10 | $2.63 | $3.29 | -0.06% |
| Week 2 | $1.91 | $2.63 | $3.61 | -0.12% |
| Week 3 | $1.78 | $2.63 | $3.88 | -0.19% |
| Week 4 | $1.67 | $2.62 | $4.11 | -0.25% |
| Week 5 | $1.59 | $2.62 | $4.34 | -0.31% |
| Week 6 | $1.51 | $2.62 | $4.55 | -0.37% |
| Week 7 | $1.44 | $2.62 | $4.75 | -0.43% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Indaptus Therapeutics, Inc. is a clinical biotechnology company that engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Indaptus Therapeutics, Inc. (INDP) is the asset with a current price around $2.63 per share and a market capitalization of $350.43M, with a market rank of 3342. The current price and market position place the stock among smaller-cap healthcare names in the biotechnology space.
The price outlook is laid out across 2026–2050 with a range of potential outcomes. Forecasts show a path that includes neutral valuation in some years and bullish momentum in others, with significant upside potential by the end of the period.
A major floor 59.7% below — a decisive break under it would weaken the trend.
The nearest floor, 45.2% below — buyers have tended to step in here.
The nearest ceiling, 80.6% above — a clean break opens room to run.
A major ceiling 137.6% above — clearing it would confirm fresh momentum.
Key INDP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INDP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.62 | Buy | $2.66 | Sell |
| MA 10 | $2.85 | Sell | $2.83 | Sell |
| MA 20 | $3.29 | Sell | $2.92 | Sell |
| MA 50 | $2.51 | Buy | $2.72 | Sell |
| MA 100 | $2.33 | Buy | $2.67 | Sell |
| MA 200 | $2.53 | Buy | $4.37 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.06 | Neutral |
| Stoch RSI (14) | 18.61 | Buy |
| CCI (20) | -97.58 | Neutral |
| Williams %R (14) | -86.42 | Info |
| MACD (12,26,9) | -0.15 | Sell |
| ROC (12) | -29.11 | Sell |
| Bollinger %B (20,2) | 0.19 | Neutral |
| Stochastic %K (14) | 13.58 | Buy |
| TRIX (15) | 0.83 | Buy |
| Awesome (5,34) | -0.17 | Sell |
| Ultimate (7,14,28) | 30.35 | Neutral |
| Momentum (10) | -0.63 | Sell |
| Aroon Osc (25) | -12.00 | Sell |
| Hull MA (9) | 2.42 | Buy |
| ADX (14) | 13.46 | Neutral |
| ATR (14) | 0.25 | Info |
The near-term technical picture is neutral. RSI14 is 50, which sits in the middle of the typical range. The stock trades around SMA50 at $2.51 and SMA200 at $2.53, suggesting a balanced moving-average backdrop.
With a 30-day range of $1.50 to $4.61, traders should note the stock has a defined support at $1.44 and resistance at $4.75. Annualized volatility sits at 200%, indicating substantial price swings and risk in the short term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.06 | $2.63 | $3.95 | 0% | Neutral | |
| $2.52 | $3.48 | $5.19 | +32% | Bullish | |
| $2.34 | $3.43 | $5.45 | +31% | Bullish | |
| $1.87 | $2.88 | $4.81 | +10% | Neutral | |
| $1.99 | $3.21 | $5.58 | +22% | Bullish | |
| $1.70 | $2.87 | $5.16 | +9% | Neutral | |
| $1.48 | $2.61 | $4.84 | -1% | Neutral | |
| $2.23 | $4.10 | $7.81 | +56% | Bullish | |
| $2.33 | $4.45 | $8.68 | +69% | Bullish | |
| $2.12 | $4.20 | $8.39 | +60% | Bullish | |
| $2.25 | $5.01 | $11.00 | +90% | Bullish | |
| $3.75 | $8.33 | $19.16 | +217% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.06 | $2.63 | $3.17 | +0.00% |
| August 2026 | $2.03 | $2.46 | $3.11 | -6.28% |
| September 2026 | $2.12 | $2.61 | $3.36 | +5.84% |
| October 2026 | $2.32 | $2.88 | $3.78 | +10.46% |
| November 2026 | $2.32 | $2.91 | $3.87 | +1.07% |
| December 2026 | $2.31 | $2.93 | $3.95 | +0.71% |
Click any year to see its month-by-month INDP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, INDP could reach as high as $3.95, with a base case around $2.63 and support toward $1.06 — roughly 0% from $2.63. Price action looks broadly range-bound.
Expect INDP to range from $2.52 to $5.19 through 2027. The $3.48 average target implies a +32% move from current prices. That is up +32% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The INDP price prediction for 2028 points to an average of $3.43 (low $2.34, high $5.45) — a potential gain of +31% on today's $2.63. Momentum favours further upside here.
In 2029, INDP is projected to trade between $1.87 and $4.81, averaging $2.88 — a potential gain of +10% from today's $2.63. That is -16% versus the projected 2028 average. A consolidation phase looks the most probable path here.
Indaptus Therapeutics, Inc.'s 2030 outlook centres on $3.21, within a $1.99 to $5.58 range. That is up +11% on the projected 2029 average. That marks a +22% change versus current levels. Momentum favours further upside here.
By 2031, INDP could reach as high as $5.16, with a base case around $2.87 and support toward $1.70 — roughly +9% from $2.63. A consolidation phase looks the most probable path here.
Expect INDP to range from $1.48 to $4.84 through 2032. The $2.61 average target implies a -1% move from current prices. That is -9% versus the projected 2031 average. Price action looks broadly range-bound.
The INDP price prediction for 2033 points to an average of $4.10 (low $2.23, high $7.81) — a potential gain of +56% on today's $2.63. Buyers look set to stay in control over this stretch.
In 2034, INDP is projected to trade between $2.33 and $8.68, averaging $4.45 — a potential gain of +69% from today's $2.63. That is up +8% on the projected 2033 average. Momentum favours further upside here.
Indaptus Therapeutics, Inc.'s 2035 outlook centres on $4.20, within a $2.12 to $8.39 range. That is -6% versus the projected 2034 average. That marks a +60% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, INDP could reach as high as $11.00, with a base case around $5.01 and support toward $2.25 — roughly +90% from $2.63. Momentum favours further upside here.
Expect INDP to range from $3.75 to $19.16 through 2050. The $8.33 average target implies a +217% move from current prices. That is up +66% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in INDP today (≈ 380.228137 INDP) could be worth
$3,168.05
+$2,168.05 (+217%) by 2050 · US Dollar
Based on the average projected INDP price of $8.33 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INDPwould be worth at today's price.
$1,000 invested in INDP on Jul 10, 2025 (≈ 81.037276 INDP) would be worth
$213.13
-$786.87 (-78.7%) today · 0.21× · US Dollar
Based on a INDP entry price of $12.34 vs. today's $2.63.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.03 | $867.99 | -13.2% |
| 1 month ago | $2.45 | $1,073.47 | +7.3% |
| 3 months ago | $2.11 | $1,246.45 | +24.6% |
| 6 months ago | $3.15 | $834.92 | -16.5% |
| 1 year ago | $12.34 | $213.13 | -78.7% |
| All time (5.0y) ago | $378.56 | $6.95 | -99.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INDP forecast.
Our base-case forecast reaches $5.30 around 2050.
Implied market cap at $5.30: $706.18M
The multi-year forecast shows varying returns across the horizon, with several bullish years and some neutral ones. For 2026 the avg price is $2.63 with a min of $1.06 and a max of $3.95, and 0.0% ROI, with NEUTRAL sentiment. In 2027 the avg rises to $3.48 with a min of $2.52 and a max of $5.19, a 32.3% ROI, and a BULLISH tone.
The following year, 2028, shows an avg of $3.43, a min of $2.34, a max of $5.45, a 30.6% ROI, and BULLISH sentiment.
In 2029 the forecast trades at an avg of $2.88 (min $1.87, max $4.81) with a 9.7% ROI and NEUTRAL sentiment. The 2030 outlook brands an avg of $3.21 (min $1.99, max $5.58) and 22.2% ROI with BULLISH sentiment. The years 2031 and 2032 show more muted results (avg $2.87 and $2.61 respectively) with neutral sentiment and a small negative ROI of -0.7% in 2032.
From 2033 onward, the forecast turns more bullish: 2033 avg $4.10 (min $2.23, max $7.81) with 56.1% ROI; 2034 avg $4.45 (min $2.33, max $8.68) with 69.1% ROI; 2035 avg $4.20 (min $2.12, max $8.39) with 59.7% ROI, all labeled BULLISH.
The long-range view extends to 2040 with an avg price of $5.01 and a 90.5% ROI, plus a max of $11.00 and a min of $2.25, continuing the BULLISH sentiment. By 2050, the avg price is projected at $8.33 with a max of $19.16 and a min of $3.75, representing a 216.8% ROI and BULLISH sentiment. These figures are estimates and not guarantees, reflecting projected paths under varying conditions.
Tap a question to reveal the answer.
In 2030, the forecast shows an avg price of $3.21 with a min of $1.99 and a max of $5.58; ROI is 22.2% and sentiment is BULLISH.
The forecast includes multiple bullish years (e.g., 2027 avg $3.48, ROI 32.3; 2028 avg $3.43, ROI 30.6; 2033–2035 all bullish; 2040 avg $5.01, ROI 90.5; 2050 avg $8.33, ROI 216.8) alongside neutral years and one year with a small negative ROI (-0.7% in 2032). These are estimates, not guarantees.
Yes. The max values in the forecast exceed $10 in some years: 2040 max $11.00 and 2050 max $19.16.
Current price is $2.63 and market cap is $350.43M. The stock rank is 3342.
For 2027, the avg price is $3.48 with a min of $2.52 and a max of $5.19, ROI of 32.3%, and sentiment BULLISH.
Indaptus Therapeutics, Inc. Community Discussion
0Share your Indaptus Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.